To view enhanced content for this article go to http://www.medengine.com/Redeem/8C47F060217D0440
In a phase 2 trial of natalizumab in Japanese patients with relapsing-remitting multiple sclerosis (RRMS), treatment-related changes in relapses, brain lesions, and disability worsening were found to be comparable with those observed in the phase 3 studies of natalizumab in primarily non-Asian RRMS patients.
This subanalysis of the placebo-controlled phase 2 trial of natalizumab in Japanese RRMS patients (n = 94) evaluated the effects of natalizumab versus placebo on the proportion of patients who achieved relapse-free, T1 gadolinium-enhancing (Gd+) lesion-free, and new/newly enlarged T2 lesion-free status, defined as “no evidence of inflammatory disease activity” (NEDA)–like status, after 24 weeks of treatment.
In this subanalysis, significantly more natalizumab-treated than placebo-treated patients achieved NEDA-like status (76.6% vs. 31.9%; P < 0.0001). In addition, the odds ratio (95% confidence interval) for patients on natalizumab to reach NEDA-like status was 6.98 (2.80–17.38) compared with placebo patients.
These results confirm previous findings indicating that natalizumab is efficacious in Japanese patients with RRMS.
Trial Registration: ClinicalTrials.gov identifier, NCT01440101.
Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254–60. CrossRefPubMed
Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329–37. CrossRefPubMed
Havrdova E, Gold R, Fox R, Kappos L, Phillips J, Zhang A, et al. BG-12 (dimethyl fumarate) treatment for relapsing-remitting multiple sclerosis (RRMS) increases the proportion of patients free of measured clinical and neuroradiologic disease activity in the phase 3 studies. The American Academy of Neurology 65th Annual Meeting, March 16–23, 2013, San Diego, CA.
Khatri B, Barkhof F, Comi G, Jin J, Francis G, Cohen J. Fingolimod treatment increases the proportion of patients who are free from disease activity in multiple sclerosis compared to interferon beta-1a: results from a phase 3 active-controlled study (TRANSFORMS). The American Academy of Neurology 64th Annual Meeting, April 21–28, 2012, New Orleans, LA.
Barkhof F, Cohen J, Radue E, Kappos L, Calabresi P, Häring D, et al. Brain volume changes, on-study correlations and the link to disability in three fingolimod phase 3 studies. The 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, October 2–5, 2013, Copenhagen, Denmark.
- Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis
J. T. Tibung
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II